Hydroxyzine: Drug information

For additional information see "Hydroxyzine: Patient drug information" and "Hydroxyzine: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table

Brand Names: US

Vistaril [DSC]

Brand Names: Canada

Atarax;
NOVO-Hydroxyzin [DSC];
PMS-HydrOXYzine HCl [DSC]

Pharmacologic Category

Antiemetic;
Histamine H₁ Antagonist;
Histamine H₁ Antagonist, First Generation;
Piperazine Derivative

Dosing: Adult

Anxiety, monotherapy or adjunctive therapy

Anxiety, monotherapy or adjunctive therapy (alternative agent):

Note: May be useful for insomnia associated with anxiety or for short-term immediate control of symptoms until maintenance therapy is effective (Ref).

Oral: Usual dosage range: 25 to 50 mg up to 4 times daily, as needed; may increase based on response and tolerability up to 400 mg/day; maximum single dose: 100 mg. For insomnia associated with anxiety, administer at bedtime (Ref).

Peripartum management, adjunct to opioids

Peripartum management, adjunct to opioids:

Note: May be used to potentiate opioid analgesia and decrease side effects (eg, nausea and vomiting).

IM: 25 to 50 mg as a single dose; may repeat after 4 hours if needed (Ref).

Pruritus

Pruritus:

Manufacturer’s dosing: Oral: 25 mg 3 to 4 times daily as needed.

Nightly dosing: Oral: Due to its sedating properties, some experts recommend 25 to 50 mg once daily as needed at bedtime (Ref).

Urticaria, new onset and chronic spontaneous

Urticaria, new onset and chronic spontaneous (alternative agent):

Note: Second-generation H₁-antihistamines are preferred due to less sedating and anticholinergic effects (Ref). May consider use in combination with a second-generation H₁-antihistamine in patients in whom bedtime sedating effects may be beneficial, or as initial parenteral therapy in patients with new-onset urticaria in whom more rapid onset of action is desired; avoid use in patients with high-risk occupations (eg, pilots, bus drivers) or who may be more prone to anticholinergic effects (eg, older adults) (Ref).

Oral: Initial: 10 to 25 mg at bedtime. May increase in 10 to 25 mg increments at weekly intervals if needed based on response and tolerability; daily dose may be administered at bedtime or in 3 to 4 divided doses (Ref). Some experts administer daily doses >100 mg in divided doses; do not exceed 200 mg/day (Ref).

IM (for new onset urticaria only): 25 to 50 mg 3 to 4 times per day as needed (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: There are no data on hydroxyzine pharmacokinetics in kidney impairment; however, the active metabolite, cetirizine, is cleared by the kidney and may accumulate in patients with kidney impairment (Ref). Additionally, hydroxyzine was associated with QTc prolongation in a cohort of patients with chronic kidney insufficiency (Ref).

Altered kidney function:

Oral, IM:

CrCl ≥50 mL/minute: No dosage adjustment necessary (Ref).

CrCl 10 to <50 mL/minute: Administer ~50% of usual dose (Ref).

CrCl <10 mL/minute: Administer ~25% to 50% of usual dose (Ref).

Hemodialysis, intermittent (thrice weekly): Hydroxyzine is unlikely to be significantly dialyzed (large V_d (Ref)) and its metabolite (cetirizine) is <10% dialyzable (Ref):

Oral, IM: Administer 25% to 50% of usual dose (Ref).

Uremic pruritus: Oral: 10 to 25 mg once or twice daily as needed (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (large V_d) (Ref):

Oral, IM: Administer 25 to 50% of usual dose (Ref).

Uremic pruritus: Oral: 10 to 25 mg once or twice daily as needed (Ref).

CRRT: Oral, IM: Administer 50% of usual dose (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral, IM: Administer 50% of usual dose (Ref).

Dosing: Liver Impairment: Adult

The liver dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.

Note: Hydroxyzine is primarily metabolized in the liver to the active metabolite, cetirizine (Ref). Hydroxyzine elimination half-life is prolonged in patients with liver impairment, which may increase the likelihood of sedation; therefore, use with caution in patients with hepatic encephalopathy (Ref). There is insufficient data on the long-term use of hydroxyzine in patients with liver impairment (Ref).

Liver impairment prior to treatment initiation :

Initial or dose titration in patients with preexisting liver cirrhosis:

Child-Turcotte-Pugh class A to C: IM, Oral: Use minimum effective dose, not to exceed a total maximum daily dose of 25 mg/day (Ref).

Liver impairment developing in patients already receiving hydroxyzine:

Chronic disease progression (eg, outpatient):

Progression from baseline to Child-Turcotte-Pugh class A to C: IM, Oral: Use minimum effective dose, not to exceed a total maximum daily dose of 25 mg/day (Ref).

Acute worsening of liver function (eg, requiring hospitalization):

Child-Turcotte-Pugh class A to C: IM, O ral: Use minimum effective dose, not to exceed a total maximum daily dose of 25 mg/day; discontinue use if new or worsening hepatic encephalopathy (Ref).

Dosing: Older Adult

Avoid use (Ref).

Dosing: Pediatric

(For additional information see "Hydroxyzine: Pediatric drug information")

Anxiety

Anxiety: Note: Although FDA approved for use in anxiety, data in pediatric patients are sparse; expert recommendations for pediatric patients do not consider hydroxyzine a therapeutic option for the management of anxiety disorders (eg, generalized anxiety disorder, separation anxiety, specific phobias, panic disorder, post-traumatic stress disorder); use has generally been replaced by newer, more effective agents (Ref). In adults, a lower daily dosing regimen of 37.5 to 75 mg/day in divided doses is recommended by experts (Ref).

Children <6 years: Oral: 12.5 mg 4 times daily (Ref); although FDA approved, expert guidelines do not recommend pharmacotherapy in patients <6 years of age (Ref).

Children ≥6 years and Adolescents: Oral: 12.5 to 25 mg 4 times daily (Ref).

Nausea and vomiting

Nausea and vomiting: Note: Expert recommendations for postoperative nausea and vomiting (PONV) management do not suggest hydroxyzine as a therapeutic option; use has typically been replaced by newer agents with an improved safety profile (Ref).

Infants, Children, and Adolescents: IM: 1.1 mg/kg/dose; maximum dose: 100 mg/dose.

Pruritus; associated with allergic conditions or chronic urticaria

Pruritus; associated with allergic conditions or chronic urticaria:

Age-directed dosing:

Children <6 years: Oral: 12.5 mg 3 to 4 times daily (Ref).

Children ≥6 years and Adolescents: Oral: 12.5 to 25 mg 3 to 4 times daily (Ref). Note: Based on pharmacokinetic studies, dosing once daily (at bedtime) or twice daily may be adequate due to the long half-life (Ref).

Weight-directed dosing:

Children and Adolescents:

Patient weight ≤40 kg: Oral: 2 mg/kg/day divided every 6 to 8 hours as needed; maximum dose: 25 mg/dose. Note: Based on pharmacokinetic studies, dosing once daily (at bedtime) or twice daily may be adequate due to the long half-life (Ref).

Patient weight >40 kg: Oral: 25 to 50 mg once daily at bedtime or twice daily (Ref).

Pruritus; associated with opioid use

Pruritus; associated with opioid use: Limited data available: Children and Adolescents: IM, Oral: 0.5 mg/kg/dose every 6 hours as needed; usual maximum dose: 50 mg/dose (Ref).

Sedation; pre-/postoperative, adjunctive therapy

Sedation; pre-/postoperative, adjunctive therapy: Note: Although FDA approved, pre-/postoperative hydroxyzine use has largely been replaced by other agents.

Oral: Children and Adolescents: Oral: 0.6 mg/kg/dose; maximum dose: 100 mg/dose.

IM: Infants, Children, and Adolescents: IM: 1.1 mg/kg/dose; maximum dose: 100 mg/dose.

Sedation; procedural, adjunctive therapy

Sedation; procedural, adjunctive therapy (eg, dental, echocardiography): Limited data available:

Children 2 to 12 years: Oral: 1 mg/kg/dose as a single dose 30 to 45 minutes prior to procedure in combination with other sedatives (eg, midazolam, chloral hydrate) has been used in children prior to dental procedures or echocardiograms; maximum dose: 100 mg/dose (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Altered kidney function:

Note: There are no data on hydroxyzine pharmacokinetics in kidney impairment; however, based on adult data, the active metabolite, cetirizine, is cleared by the kidney and may accumulate in patients with kidney impairment (Ref). Additionally, hydroxyzine was associated with QTc prolongation in a cohort of adult patients with chronic kidney insufficiency (Ref).

Children and Adolescents: Oral, IM:

Mild impairment: No dosage adjustment necessary (Ref).

Moderate to severe impairment: Administer ~50% of usual dose (Ref).

Hemodialysis, intermittent: Hydroxyzine is unlikely to be significantly dialyzed (due to large V_d (Ref)) and its metabolite (cetirizine) is <10% dialyzable (Ref).

Dosing: Liver Impairment: Pediatric

There are no pediatric-specific recommendations; based on experience in adults with primary biliary cirrhosis, increasing length of dosing interval is recommended (Ref).

Adverse Reactions (Significant): Considerations

Acute generalized exanthematous pustulosis

Acute generalized exanthematous pustulosis (AGEP) has rarely been reported (Ref). Resolution generally occurs 2 weeks after drug discontinuation (Ref); although, with hydroxyzine, may occur within 3 days (Ref).

Mechanism: Non–dose-related; immunologic. AGEP is considered a T-cell mediated reaction (Ref).

Onset: Delayed: usually within 24 hours after drug initiation (Ref).

Risk factors:

• Cross-sensitivity: Not established; conflicting evidence regarding cross-reactivity between hydroxyzine, cetirizine, and levocetirizine (Ref)

CNS depression

Drowsiness and dizziness may occur, especially after initial doses. These effects may persist the next morning after bedtime dosing causing daytime drowsiness (Ref). Drowsiness is usually transient and subsides after a few consecutive days of therapy or after dose reduction (Ref). Cognitive dysfunction has been reported after morning and evening dosing, which may impair the ability to drive or operate machinery (Ref). At recommended doses, clinically significant respiratory depression has not been observed.

Mechanism : Dose related; related to the pharmacologic action (ie, competitive binding to histamine-₁ receptors in the CNS) (Ref).

Onset: Rapid; occurs within the first few days of therapy initiation (Ref)

Risk factors:

• Dose (especially initiation) (Ref)

• Concurrent use of other CNS depressant medications

• Concurrent use of alcohol (Ref)

• Age >65 years (Ref)

QT prolongation

Hydroxyzine is associated with a conditional risk of prolonged QT interval on ECG, defined as a QTc >500 msec (Ref). Hydroxyzine-related QT prolongation and torsades de pointes (TdP) have been described in case reports (Ref). QTc values return to normal within days to weeks after drug discontinuation (Ref).

Mechanism: Human ether-à-go-go (hERG) channel inhibition leading to prolongation of the cardiac action potential (Ref).

Onset: Rapid; typically occurs within 5 days after initial dose (Ref).

Risk factors:

Drug-induced QTc prolongation/TdP (in general):

• Females (Ref)

• Age >65 years (Ref)

• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (Ref)

• Genetic defects of cardiac ion channels (Ref)

• History of drug-induced TdP (Ref)

• Congenital long QT syndrome (Ref)

• Baseline QTc interval prolongation (eg, >500 msec) or lengthening of the QTc by ≥60 msec (Ref)

• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (Ref)

• Bradycardia (Ref)

• Hepatic impairment (Ref)

• Kidney impairment (Ref)

• Diuretic use (Ref)

• Sepsis (Ref)

• Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (Ref)

Drug-specific:

• hERG gene mutation (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Frequency not defined:

Gastrointestinal: Xerostomia

Nervous system: Drowsiness (transient)

Respiratory: Respiratory depression (high doses)

Postmarketing:

Cardiovascular: Prolonged QT interval on ECG (rare: <1%) (Ref), torsades de pointes (rare: <1%) (Ref)

Dermatologic: Acute generalized exanthematous pustulosis (rare: <1%) (Ref), pruritus, skin rash, urticaria

Hypersensitivity: Fixed drug eruption (Ref)

Nervous system: Cognitive dysfunction (Ref), hallucination, headache, involuntary body movements, seizure (high doses)

Neuromuscular & skeletal: Tremor (high doses)

Contraindications

Hypersensitivity to hydroxyzine or any component of the formulation; early pregnancy; prolonged QT interval.

Additional contraindications:

Oral: Hypersensitivity to cetirizine or levocetirizine.

Injection: SUBQ, intra-arterial, or IV administration.

Canadian labeling: Additional contraindications (not in US labeling): Oral: Hypersensitivity to other piperazine derivatives, aminophylline or ethylenediamine; history of torsade de pointes, including congenital long QT syndromes; history of cardiac arrhythmias; significant electrolyte imbalance (eg, hypokalemia, hypomagnesemia); significant bradycardia; family history of sudden cardiac death; concomitant use with other QT/QTc-prolonging drugs or with CYP3A4/5 inhibitors; asthmatics who have previously experienced a serious anti-histamine induced adverse bronchopulmonary effect; porphyria; patients of childbearing potential.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• QT prolongation/torsades de pointes: Oral hydroxyzine is contraindicated in patients with a prolonged QT interval.

Disease-related concerns:

• Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.

• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.

• Respiratory disease: Use with caution in patients with asthma or chronic obstructive pulmonary disease (COPD).

Special populations:

Older adult: May cause over sedation in older adults; avoid use.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.

Other warnings/precautions:

• Appropriate administration: Parenteral: For IM use only. Severe injection-site reactions have been reported with IM administration (eg, extensive tissue damage, necrosis, gangrene) requiring surgical intervention (including debridement, skin grafting, and amputation). SUBQ, IV, and intra-arterial routes of administration are contraindicated. Intravascular hemolysis, thrombosis, and digital gangrene have been reported with IV or intra-arterial administration (Baumgartner 1979); SUBQ administration may result in significant tissue damage. If inadvertent IV administration results in extravasation, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity.

• Long-term use: The effectiveness of hydroxyzine for long-term use (>4 months) has not been assessed; periodically reassess use.

Warnings: Additional Pediatric Considerations

Neonatal withdrawal symptoms, including seizures, have been reported following long-term maternal use or the use of large doses near term (Serreau 2005).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as pamoate:

Vistaril: 25 mg [DSC], 50 mg [DSC]

Generic: 25 mg, 50 mg, 100 mg

Solution, Intramuscular, as hydrochloride:

Generic: 25 mg/mL (1 mL); 50 mg/mL (1 mL, 2 mL)

Syrup, Oral, as hydrochloride:

Generic: 10 mg/5 mL (25 mL, 118 mL, 473 mL)

Tablet, Oral, as hydrochloride:

Generic: 10 mg, 25 mg, 50 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (hydrOXYzine Pamoate Oral)

25 mg (per each): $0.21 - $0.57

50 mg (per each): $0.22 - $0.61

100 mg (per each): $1.19

Solution (hydrOXYzine HCl Intramuscular)

25 mg/mL (per mL): $35.11

50 mg/mL (per mL): $38.71

Syrup (hydrOXYzine HCl Oral)

10 mg/5 mL (per mL): $0.16 - $1.27

Tablets (hydrOXYzine HCl Oral)

10 mg (per each): $0.58 - $5.34

25 mg (per each): $0.10 - $0.85

50 mg (per each): $0.41 - $1.12

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Generic: 10 mg, 25 mg, 50 mg

Solution, Intramuscular, as hydrochloride:

Generic: 50 mg/mL (1 mL)

Syrup, Oral, as hydrochloride:

Atarax: 10 mg/5 mL (473 mL) [contains alcohol, usp, menthol, sodium benzoate]

Generic: 10 mg/5 mL ([DSC])

Administration: Adult

IM: For IM use only. Aspirate before injection to avoid inadvertent injection into a blood vessel. Do NOT administer IV, SUBQ, or intra-arterially (contraindicated). Administer IM deep in large muscle. The preferred site is the upper outer quadrant of the buttock or midlateral thigh. The upper outer quadrant of the gluteal region should be used only when necessary to minimize potential damage to the sciatic nerve. The deltoid region should be only used with caution to avoid radial nerve injury. Injections should not be made in the lower or mid-third of the upper arm.

Oral: Administer without regard to food.

Administration: Pediatric

Oral: May be administered without regard to food.

Parenteral: For IM use only. SUBQ, intra-arterial, and IV administration are contraindicated and not recommended under any circumstances; intravascular hemolysis, thrombosis, and digital gangrene can occur; extravasation can result in sterile abscess and marked tissue induration (Ref).

Administer IM deep in large muscle. For IM administration in children, injections should be made into the midlateral muscles of the thigh. In infants and children, the upper outer quadrant of the gluteal region should be used only when necessary (eg, burn patients) to minimize potential damage to the sciatic nerve. In adults, the upper outer quadrant of the buttock is considered the preferred injection site. In older children and adolescents, the deltoid region should only be used if well developed and with caution to avoid radial nerve injury. Injections should not be made in the lower or mid-third of the upper arm. Aspirate before injection to avoid inadvertent injection into a blood vessel.

Use: Labeled Indications

Oral:

Anxiety: Symptomatic relief of anxiety.

Pruritus: Management of pruritus due to allergic conditions (eg, atopic and contact dermatoses) and histamine-mediated pruritus.

Urticaria, new onset and chronic spontaneous: Management of urticaria.

IM:

Peripartum management, adjunct to opioids: As prepartum and postpartum adjunctive medication to permit reduction in opioid dosage, allay anxiety, and control emesis.

Urticaria, new onset: Management of urticaria.

Medication Safety Issues

Sound-alike/look-alike issues:

HydrOXYzine may be confused with hydrALAZINE, hydroCHLOROthiazide, HYDROmorphone, hydroxyurea

Atarax may be confused with Ativan

Vistaril may be confused with Restoril, Versed, Zestril

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs (contraindicated in early pregnancy) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Community/Ambulatory Care Settings).

Older Adult: High-Risk Medication:

Beers Criteria: Hydroxyzine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. Exposure to concurrent anticholinergic drugs also increases risk of falls, delirium, and dementia; consider total anticholinergic burden when conducting medication reviews (Beers Criteria [AGS 2023]).

Hydroxyzine is identified in the Screening Tool of Older Person's Prescriptions (STOPP) criteria as a potentially inappropriate medication in older adults (≥65 years of age) due to an increased risk of falls in patients with recurrent falls. Use is not recommended for the treatment of insomnia, as first-line treatment of allergy or pruritus, or in patients with delirium or dementia (O’Mahony 2023).

International issues:

Vistaril [US and Turkey] may be confused with Vastarel brand name for trimetazidine [multiple international markets]

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Acetylcholinesterase Inhibitors. Risk C: Monitor

Aclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Alizapride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Amantadine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Amezinium: Antihistamines may increase stimulatory effects of Amezinium. Risk C: Monitor

Amisulpride (Oral): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Articaine: May increase CNS depressant effects of CNS Depressants. Management: Consider reducing the dose of articaine if possible when used in patients who are also receiving CNS depressants. Monitor for excessive CNS depressant effects with any combined use. Risk D: Consider Therapy Modification

Azelastine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Benperidol: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Benperidol. Risk C: Monitor

Benperidol: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Benztropine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Benztropine. Risk C: Monitor

Benzylpenicilloyl Polylysine: Coadministration of Antihistamines and Benzylpenicilloyl Polylysine may alter diagnostic results. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Risk D: Consider Therapy Modification

Betahistine: Antihistamines may decrease therapeutic effects of Betahistine. Betahistine may decrease therapeutic effects of Antihistamines. Risk C: Monitor

Biperiden: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Biperiden. Risk C: Monitor

Blonanserin: CNS Depressants may increase CNS depressant effects of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider Therapy Modification

Bornaprine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Botulinum Toxin-Containing Products: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Brimonidine (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Bromopride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Bromperidol: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Buclizine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Buclizine. Risk C: Monitor

Buclizine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Buprenorphine: CNS Depressants may increase CNS depressant effects of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider Therapy Modification

BusPIRone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Cannabinoid-Containing Products: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of Cannabinoid-Containing Products. Risk C: Monitor

Cannabinoid-Containing Products: CNS Depressants may increase CNS depressant effects of Cannabinoid-Containing Products. Risk C: Monitor

Certoparin: Antihistamines may increase therapeutic effects of Certoparin. Risk C: Monitor

Cetirizine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk D: Consider Therapy Modification

Chloral Hydrate/Chloral Betaine: CNS Depressants may increase CNS depressant effects of Chloral Hydrate/Chloral Betaine. Management: Consider alternatives to the use of chloral hydrate or chloral betaine and additional CNS depressants. If combined, consider a dose reduction of either agent and monitor closely for enhanced CNS depressive effects. Risk D: Consider Therapy Modification

Chlormethiazole: May increase CNS depressant effects of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider Therapy Modification

Chlorphenesin Carbamate: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor

Cimetropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Cimetropium. Risk X: Avoid

CloZAPine: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider Therapy Modification

CNS Depressants: HydrOXYzine may increase CNS depressant effects of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider Therapy Modification

Daridorexant: May increase CNS depressant effects of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification

Darifenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Darifenacin. Risk C: Monitor

DexmedeTOMIDine: CNS Depressants may increase CNS depressant effects of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider Therapy Modification

Dicyclomine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Dicyclomine. Risk C: Monitor

Difelikefalin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Dihydralazine: CNS Depressants may increase hypotensive effects of Dihydralazine. Risk C: Monitor

Dimethindene (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Dothiepin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

DroNABinol: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of DroNABinol. Risk X: Avoid

DroPERidol: May increase CNS depressant effects of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider Therapy Modification

Eluxadoline: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Eluxadoline. Risk X: Avoid

Emedastine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk C: Monitor

Entacapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Fesoterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Fesoterodine. Risk C: Monitor

Flunarizine: CNS Depressants may increase CNS depressant effects of Flunarizine. Risk X: Avoid

Flunitrazepam: CNS Depressants may increase CNS depressant effects of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider Therapy Modification

Gastrointestinal Agents (Prokinetic): Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Gastrointestinal Agents (Prokinetic). Risk C: Monitor

Gepotidacin: May decrease anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Glucagon: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor

Glycopyrrolate (Oral Inhalation): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Oral Inhalation). Risk X: Avoid

Glycopyrrolate (Systemic): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Systemic). Risk C: Monitor

Glycopyrronium (Topical): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Hyaluronidase: Antihistamines may decrease therapeutic effects of Hyaluronidase. Risk C: Monitor

Ipratropium (Nasal): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ipratropium (Oral Inhalation): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Itopride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Itopride. Risk C: Monitor

Ixabepilone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Kava Kava: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Ketotifen (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Kratom: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Lemborexant: May increase CNS depressant effects of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider Therapy Modification

Levocetirizine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Levosulpiride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Levosulpiride. Risk X: Avoid

Lisuride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Lofexidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Loxapine: CNS Depressants may increase CNS depressant effects of Loxapine. Management: Consider reducing the dose of CNS depressants administered concomitantly with loxapine due to an increased risk of respiratory depression, sedation, hypotension, and syncope. Risk D: Consider Therapy Modification

Magnesium Sulfate: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Melperone: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Mequitazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Metergoline: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Methotrimeprazine: CNS Depressants may increase CNS depressant effects of Methotrimeprazine. Methotrimeprazine may increase CNS depressant effects of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider Therapy Modification

Methscopolamine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Methscopolamine. Risk C: Monitor

Metoclopramide: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

MetyroSINE: CNS Depressants may increase sedative effects of MetyroSINE. Risk C: Monitor

Minocycline (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Mirabegron: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Mirabegron. Risk C: Monitor

Moxonidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Nabilone: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Nitroglycerin: Agents with Clinically Relevant Anticholinergic Effects may decrease absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor

Noscapine: CNS Depressants may increase adverse/toxic effects of Noscapine. Risk X: Avoid

Olopatadine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Opicapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Opioid Agonists: CNS Depressants may increase CNS depressant effects of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification

Opipramol: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Opipramol: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Orphenadrine: CNS Depressants may increase CNS depressant effects of Orphenadrine. Risk X: Avoid

Oxatomide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Oxomemazine: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

OxyBUTYnin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of OxyBUTYnin. Risk C: Monitor

OxyCODONE: CNS Depressants may increase CNS depressant effects of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification

Paraldehyde: CNS Depressants may increase CNS depressant effects of Paraldehyde. Risk X: Avoid

Perazine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Periciazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Perphenazine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Perphenazine. Risk C: Monitor

Pipamperone: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor

Piribedil: CNS Depressants may increase CNS depressant effects of Piribedil. Risk C: Monitor

Pitolisant: Antihistamines may decrease therapeutic effects of Pitolisant. Risk X: Avoid

Potassium Chloride: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid

Potassium Citrate: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid

Pramipexole: CNS Depressants may increase sedative effects of Pramipexole. Risk C: Monitor

Pramlintide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. These effects are specific to the GI tract. Risk X: Avoid

Procarbazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Propantheline: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Propantheline. Risk C: Monitor

Propiverine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

QT-prolonging Agents (Highest Risk): HydrOXYzine may increase QTc-prolonging effects of QT-prolonging Agents (Highest Risk). Risk C: Monitor

QuiNIDine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ramosetron: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Ramosetron. Risk C: Monitor

Revefenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Revefenacin. Risk X: Avoid

Rilmenidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Rivastigmine: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Rivastigmine. Rivastigmine may decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider Therapy Modification

Ropeginterferon Alfa-2b: CNS Depressants may increase adverse/toxic effects of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider Therapy Modification

ROPINIRole: CNS Depressants may increase sedative effects of ROPINIRole. Risk C: Monitor

Rotigotine: CNS Depressants may increase sedative effects of Rotigotine. Risk C: Monitor

Secretin: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider Therapy Modification

Sofpironium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Sofpironium. Risk X: Avoid

Suvorexant: CNS Depressants may increase CNS depressant effects of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification

Thalidomide: CNS Depressants may increase CNS depressant effects of Thalidomide. Risk X: Avoid

Thiazide and Thiazide-Like Diuretics: Agents with Clinically Relevant Anticholinergic Effects may increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Tiapride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Tiapride. Risk C: Monitor

Tiotropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tiotropium. Risk X: Avoid

Tolterodine: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tolterodine. Risk C: Monitor

Tranylcypromine: May increase anticholinergic effects of Antihistamines, First Generation. Risk X: Avoid

Trospium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trospium. Risk C: Monitor

Umeclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Valerian: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Zolpidem: CNS Depressants may increase CNS depressant effects of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider Therapy Modification

Zuranolone: May increase CNS depressant effects of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider Therapy Modification

Pregnancy Considerations

Hydroxyzine crosses the placenta (Prenner 1977; Serreau 2005).

Based on data from animal reproduction studies, the use of hydroxyzine in early pregnancy is contraindicated. Outcome data following maternal use of hydroxyzine in humans during pregnancy are available (Etwel 2017; Hansen 2020; Heinonen 1977; Kocatürk 2022). Possible withdrawal symptoms have been observed in neonates following chronic maternal use of hydroxyzine during pregnancy (Prenner 1977; Serreau 2005).

Hydroxyzine is approved for pre- and postpartum adjunctive therapy to control emesis, reduce opioid dosage, and treat anxiety. However, agents other than hydroxyzine are recommended for the treatment of nausea and vomiting of pregnancy (ACOG 189 2018).

Algorithms are available for the treatment of urticaria. First-generation oral antihistamines are generally not recommended for use in pregnant patients due to side effects (EAACI [Zuberbier 2022]).

Breastfeeding Considerations

It is not known if hydroxyzine is present in breast milk.

Drowsiness and irritability have been reported in breastfed infants exposed to antihistamines (Ito 1993). Sedation has been reported in breastfed infants exposed to hydroxyzine (Soussan 2014). In general, if a breastfed infant is exposed to a first-generation antihistamine via breast milk, they should be monitored for irritability or drowsiness (Butler 2014).

Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of lactation (Messinis 1985).

Use of a second-generation antihistamine is preferred when an oral antihistamine is needed in lactating patients (EAACI [Zuberbier 2022], Butler 2014).

Monitoring Parameters

Relief of symptoms, mental status and alertness, BP, rash (including worsening of pre-existing skin reactions), signs/symptoms of hypersensitivity reaction.

Mechanism of Action

Competes with histamine for H₁-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract (Simons 1994). Possesses skeletal muscle relaxing, bronchodilator, antihistamine, antiemetic, and analgesic properties. Activity at muscarinic, serotonergic (5HT2), and dopaminergic receptors in the hippocampus, cerebral cortices, and whole brain may produce anxiolytic effects (Guaiana 2010; Sawantdesai 2016).

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Oral: 15 to 30 minutes; IM: Rapid.

Duration: Decreased histamine-induced wheal and flare areas: 2 to ≥36 hours; Suppression of pruritus: 1 to 12 hours (Simons 1984a).

Absorption: Oral: Rapid.

Distribution: Children and Adolescents 1 to 14 years: 18.5 ± 8.6 L/kg (Simons 1984b); Adults: V_d: 16 ± 3 L/kg (Simons 1984a); Elderly: ~23 L/kg (Simons 1989b); Hepatic dysfunction: ~23 L/kg (Simons 1989a).

Metabolism: Hepatic to multiple metabolites, including cetirizine (active) (Simons 1989a).

Half-life elimination:

Children and Adolescents 1 to 14 years (mean age: 6.1 ± 4.6 years): 7.1 ± 2.3 hours; Note: Half-life increased with increasing age and was 4 hours in patients 1 year of age and 11 hours in a 14-year-old patient (Simons 1984b).

Adults: ~20 hours (Simons 1984a); Elderly: ~29 hours (Simons 1989b); Hepatic dysfunction: ~37 hours (Simons 1989a).

Time to peak: Oral administration: Serum: ~2 hours; Peak suppression of antihistamine-induced wheal and flare: 4 to 12 hours (Simons 1984a).

Excretion: Urine; active metabolite (cetirizine) is renally eliminated (Simons 1994).

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Atarax;
(AR) Argentina: Ataraxone | Hidroxina | Hyderax | Panaler;
(AT) Austria: Atarax;
(AU) Australia: Atarax;
(BD) Bangladesh: Artica | Atarax | Roxyzin | Xyril;
(BE) Belgium: Atarax;
(BG) Bulgaria: Atarax | Neurolax;
(BR) Brazil: Cloridrato de hidroxizina | Dicloridrato de hidroxizina | Droxy | Hidroxine | Hixizine | Prurizin;
(CH) Switzerland: Atarax;
(CL) Chile: Dalun | Fasarax | Fedox | Nexit;
(CN) China: Hydroxyzine;
(CO) Colombia: Calmofilase | Cedar | Clemaskov | Dormirex | Drowsy | Droxia | Hiderax | Hiderax s | Hidrolan | Hidroxfar | Hidroxicina | Hidroxizina | Histaxina | Indolgin;
(CZ) Czech Republic: Atarax;
(DE) Germany: Ah3 | Atarax | Atarax pb pharma | Elroquil n | Hydroxyzin bluefish;
(DO) Dominican Republic: Atarax | Droxicin | Hidroxicina | Hyderax | Kalm | Pazz | Seda;
(EC) Ecuador: Atarax | Fasarax | Hidroxicina | Hidroxina;
(EE) Estonia: Atarax | Hydroxyzin bluefish | Hydroxyzinum vp;
(EG) Egypt: Atarax;
(ES) Spain: Atarax | Hidroxicina qualigen | Hidroxizina Bluefish;
(FI) Finland: Atarax | Hydroxyzine orifarm | Hydroxyzine sandoz;
(FR) France: Atarax | Hydroxyzine arrow | Hydroxyzine biogaran | Hydroxyzine Bluefish | Hydroxyzine Cristers | Hydroxyzine EG | Hydroxyzine mylan | Hydroxyzine renaudin | Hydroxyzine sandoz | Hydroxyzine Teva | Hydroxyzine zentiva;
(GB) United Kingdom: Atarax | Equipose | Hydroxyzine | Ucerax;
(GR) Greece: Antipsichos | Atarax | Iremofar;
(HK) Hong Kong: Allerax | Apo-hydroxyzine | Atarax | Hydroxyzine | Polizine | Qualidrozine | Rozine | Vatarax;
(HU) Hungary: Atarax;
(ID) Indonesia: Atarax | Bestalin | Iterax;
(IE) Ireland: Atarax | Ucerax;
(IL) Israel: Otarex;
(IN) India: A rex | Amwin's hysure | Anxidol | Atahist | Atarax | Atarax sr | Atazis | Atragence | Atzine | Averzine | Axaria | Braket | D rax | Dalzine hz | Galadaz | H rax | Hicope | Histozin | Hydil | Hydrax | Hydroze | Hydruvia | Hymax | Hynosure | Hyrax | Hyzine | Intoxy | Ktrax | Oltrex | Pru | Prufree | Prugo | Prunil | Prutrax | Prutrax sr | Prutrip | Psytrax | Traxsen | Unihyzi | Urtigo | Urtirid | Urtivel | Urtizen | Vistarax | Zoryz | Zylax;
(IS) Iceland: Atarax;
(IT) Italy: Atarax;
(JO) Jordan: Atarax | Newrax;
(JP) Japan: Alamon | Atarax | Atarax-p | Bobsule | Disron | Disron p | Hatanaziin merck hoei | Hatanazin | Primedoron | Vison | Warazix all | Warazix taiyo;
(KE) Kenya: Atarax;
(KR) Korea, Republic of: Adipam | Centilax | Dewbrium | Dudrizine | Hanopam | Hanwha hydroxyzine hydrochloride | Hydroxyzine | Leuzan | Phymorax | Sydraxin | Ucerax | Vistaril;
(KW) Kuwait: Atarax;
(LB) Lebanon: Atarax;
(LT) Lithuania: Atarax | Hydroxizine | Hydroxyzinum | Neurolax;
(LU) Luxembourg: Atarax;
(LV) Latvia: Atarax | Neurolax;
(MA) Morocco: Atarax | Taraxet;
(MX) Mexico: Akiskam | Apodrox | Atarax | Execut | Hidroxizina | Torefega | Xylam;
(MY) Malaysia: Apo-hydroxyzine | Atarax;
(NL) Netherlands: Atarax | Hydroxyzine-2 Hcl;
(NO) Norway: Atarax | Hydroxyzine Bluefish | Hydroxyzine orifarm | Hydroxyzine orion;
(NZ) New Zealand: Atarax | Serecid;
(OM) Oman: Atarax;
(PE) Peru: Atarax;
(PH) Philippines: Droxiem | Iterax | Sedazine;
(PK) Pakistan: Atarax | Roxyzin;
(PL) Poland: Atarax | Droxiem | Hydroxyzine orion | Hydroxyzinum | Hydroxyzinum adamed | Hydroxyzinum alvogen | Hydroxyzinum Espefa | Hydroxyzinum hasco | Hydroxyzinum polfarmex | Hydroxyzinum PPH | Hydroxyzinum vp | Hydroxyzinum zentiva;
(PR) Puerto Rico: Atarax | Hydroxyzine | Hydroxyzine HCL | Hydroxyzine Pam | Hydroxyzine pamoate | Vistaril;
(PT) Portugal: Atarax | Fenartix | Hidroxizina | Hidroxizina Bluefish | Hidroxizina generis;
(PY) Paraguay: Hidroxina | Prurid;
(QA) Qatar: Atarax;
(RO) Romania: Atarax;
(RU) Russian Federation: Atarax | Hydroxyzine | Hydroxyzine canon | Hydroxyzine nativ | Hydroxyzine vertex;
(SA) Saudi Arabia: Apo-hydroxyzine | Atarax;
(SE) Sweden: Atarax | Atyxine | Hydroxizin alternova | Hydroxyzine | Hydroxyzine Bluefish | Hydroxyzine medical valley | Hydroxyzine orifarm | Hydroxyzine orion | Vistaril;
(SG) Singapore: Aa pharma hydroxyzine | Apo-hydroxyzine | Atarax | Hizin | Navicalm | Phymorax;
(SI) Slovenia: Atarax;
(SK) Slovakia: Atarax;
(TH) Thailand: Abacus | Abelax | Abelex | Actadon | Aldrarax | Alerax-fc | Allerax | Alzin | Ammipam Ms | Andrarax | Antipru | Antizine | Antorex | Ata | Atalog | Atamed | Atano | Atarax | Ataril | Ataril F | Atarine | Atryl | Bemax | Buxie | Calmarax | Cerax | Colluzine | Darax | Dicarax | Dormirax | Drazine | Droxim | Drozine | Dyzine | Goose Hyzine | Hadarax | Hadoxine | Histan | Hiszine | Hizin | Honsa | Hycin | Hydan | Hydrarax | Hydrox | Hydroxin | Hydroxyzine | Hyrax | Hyzine | Katrax | Malax | Masarax | Morax | P.D.Rax | Pipzine | Polizine | Postarax | Prurancit | R rax | Raxta | Raxzin | Sinny | Taraxin | Trandrozine | Unamine | Unirax | Vestarax | Xara | Xaxa | Xyzine | Zeniz;
(TN) Tunisia: Atarax | Iremofar;
(TR) Turkey: Atarax | Vistaril;
(TW) Taiwan: Arax | Atarax | Disron | Nirax | Vistaril;
(UA) Ukraine: Atarax | Hydroxyzine zn;
(UY) Uruguay: Ataraxone | Hidroxin | Hidroxina;
(VN) Viet Nam: Philhydarax;
(ZA) South Africa: Aterax | Micro-hydroxyzine | Pharma Q Hydroxyzine

2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 189: nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131(1):e15-e30. [PubMed 29266076]
Acosta-Materán C, Díaz-Oliva E, Fernández-Rodríguez D, Hernández-Afonso J. QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists. J Pharmacol Pharmacother. 2016 Apr-Jun;7(2):102-5. doi:10.4103/0976-500X.184776 [PubMed 27440957]
Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
Ali Z, Ismail M, Khan F, Sajid H. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system. Expert Opin Drug Saf. 2021;20(1):101-107. doi:10.1080/14740338.2021.1846717 [PubMed 33141610]
Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 4, 2023.
Atarax (hydroxyzine) oral solution, USP [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; October 2022.
Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR. Effect of haemodialysis on the pharmacokinetics of cetirizine. Eur J Clin Pharmacol. 1990;38(1):67-69. doi:10.1007/BF00314806 [PubMed 1970299]
Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiat Clin. 2012;16:77. [PubMed 22540422]
Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, First Revision. World J Biol Psychiatry. 2008;9(4):248-312. [PubMed 18949648]
Baumgartner T. Administration of Hydroxyzine Injection. Am J Hosp Pharm. 1979;36(12):1660. [PubMed 525641]
Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. Drug Saf. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2 [PubMed 31020549]
Berde C, Ablin A, Glazer J, et al. American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer. Pediatrics. 1990;86(5 Pt 2):818-825. [PubMed 2216644]
Berns JS. Chronic kidney disease-associated pruritus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 8, 2024.
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036 [PubMed 24766875]
Bhari N, Mahajan R, Singh S, Sharma VK. Fixed drug eruption due to three antihistamines of a same chemical family: Cetirizine, levocetirizine, and hydroxyzine. Dermatol Ther. 2017;30(2). doi:10.1111/dth.12412 [PubMed 27612321]
Bushnell GA, Compton SN, Dusetzina SB, et al. Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications. J Clin Psychiatry. 2018;79(1). pii: 16m11415. [PubMed 29099547]
Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. J Am Acad Dermatol. 2014;70(3):417. doi:10.1016/j.jaad.2013.09.009 [PubMed 24528912]
Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008;15(21):2173-2191. doi:10.2174/092986708785747625 [PubMed 18781943]
Church MK, Maurer M, Simons FE, et al; Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-466. doi:10.1111/j.1398-9995.2009.02325.x [PubMed 20146728]
Chowdhury J, Vargas KG. Comparison of chloral hydrate, meperidine, and hydroxyzine to midazolam regimens for oral sedation of pediatric dental patients. Pediatr Dent. 2005;27(3):191-197. [PubMed 16173222]
Conen S, Theunissen EL, Vermeeren A, Ramaekers JG. Short-term effects of morning versus evening dose of hydroxyzine 50 mg on cognition in healthy volunteers. J Clin Psychopharmacol. 2011;31(3):294-301. doi:10.1097/JCP.0b013e318218943c [PubMed 21508863]
Connolly SD, Bernstein GA; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(2):267-283. [PubMed 17242630]
Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 15, 2021.
Dasgupta A, Wells A, Datta P. False-positive serum tricyclic antidepressant concentrations using fluorescence polarization immunoassay due to the presence of hydroxyzine and cetirizine. Ther Drug Monit. 2007;29(1):134-139. [PubMed 17333576]
DeMaso DR, Walter HJ. Psychopharmacology. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020:chap. 33.
Dykewicz MS, Wallace DV, Amrol DJ, et al; Joint Task Force on Practice Parameters; Workgroup Contributors. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007 [PubMed 32707227]
Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. Drug Saf. 2017;40(2):121-132. doi:10.1007/s40264-016-0479-9 [PubMed 27878468]
Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS,FAST, FCCP; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.
Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Fazio SB, Yosipovitch G. Pruritus: therapies for generalized pruritus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 8, 2024.
Gale CK, Millichamp J. Generalised anxiety disorder in children and adolescents. BMJ Clin Evid. 2016;2016. pii: 1002. [PubMed 26763675]
Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833 [PubMed 32467512]
Gan TJ, Diemunsch P, Habib AS, et al; Society for Ambulatory Anesthesia (SAA). Consensus guidelines for the management of postoperative nausea and vomiting [published corrections appear in Anesth Analg. 2015;120(2):494 and Anesth Analg. 2014;118(3):689]. Anesth Analg. 2014;118(1):85-113. [PubMed 24356162]
García-Gea C, Martínez J, Ballester MR, Gich I, Valiente R, Antonijoan RM. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol. 2014;29(2):120-132. doi:10.1002/hup.2378 [PubMed 24395298]
Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010;(12):CD006815. doi:10.1002/14651858.CD006815.pub2 [PubMed 21154375]
Hansen C, Desrosiers TA, Wisniewski K, Strickland MJ, Werler MM, Gilboa SM. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. Birth Defects Res. 2020;112(16):1234-1252. doi:10.1002/bdr2.1749 [PubMed 32657014]
Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Publishing Sciences Group Inc, 1977.
Hydroxyzine capsules [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; July 2018.
Hydroxyzine injection [prescribing information]. Shirley, NY: American Regent Inc; August 2016.
Hydroxyzine injection [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; May 2022.
Hydroxyzine tablets [prescribing information]. Congers, NY: Chartwell RX; March 2023.
Hydroxyzine syrup, oral solution, USP [prescribing information]. Congers, NJ: Chartwell Rx LLC; October 2022.
"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
Indraratna P, Tardo D, Delves M, Szirt R, Ng B. Measurement and management of QT interval prolongation for general physicians. J Gen Intern Med. 2020;35(3):865-873. doi:10.1007/s11606-019-05477-7 [PubMed 31654357]
Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393-1399. doi:10.1016/s0002-9378(11)90771-6 [PubMed 8498418]
Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):s1. doi:10.1186/1471-244X-14-S1-S1 [PubMed 25081580]
Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 4, 2023.
Khan M, Wakelin S. Cetirizine induced acute generalized exanthematous pustulosis confirmed by patch testing. Contact Dermatitis. 2020;82(4):238-239. doi:10.1111/cod.13443 [PubMed 31782151]
Kocatürk E, Podder I, Zenclussen AC, et al. Urticaria in pregnancy and lactation. Front Allergy. 2022;3:892673. doi:10.3389/falgy.2022.892673 [PubMed 35873599]
Kumar SL, Rai R. Hydroxyzine-induced acute generalized exanthematous pustulosis: an uncommon side effect of a common drug. Indian J Dermatol. 2011;56(4):447-448. doi:10.4103/0019-5154.84732 [PubMed 21965865]
Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63(11):1020-1027. doi:10.4088/jcp.v63n1112 [PubMed 12444816]
Malkasian GD Jr, Smith RA, Decker DG. Comparison of hydroxyzine-meperidine and promethazine-meperidine for analgesia during labor. Obstet Gynecol. 1967;30(4):568-575. [PubMed 5342863]
Martínez LG, González GEC. Cardiotoxicity of H1-antihistamines. J Anal Pharm Res. 2018;7(2):197-201. NLM ID: 101705694 [Serial]
Matzke GR, Yeh J, Awni WM, Halstenson CE, Chung M. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy. 1987;59(6 pt 2):25-30. [PubMed 2892446]
Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 1985;8(2):143-146. [PubMed 3928731]
Mohammadi Kebar S, Sharghi A, Ghorghani M, Hoseininia S. Comparison of gabapentin and hydroxyzine in the treatment of pruritus in patients on dialysis. Clin Exp Dermatol. 2020;45(7):866-871. doi:10.1111/ced.14270 [PubMed 32363638]
Nakhaee S, Nasiri A, Waghei Y, Morshedi J. Comparison of Avena sativa, vinegar, and hydroxyzine for uremic pruritus of hemodialysis patients: a crossover randomized clinical trial. Iran J Kidney Dis. 2015;9(4):316-322. [PubMed 26174460]
Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.
Noiri E, Ozawa H, Fujita T, Nakao A. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. Nephron. 2001;89(1):101-104. doi:10.1159/000046050 [PubMed 11528239]
Olacke B, Nelson T, Sarvas E, Scott JM. A retrospective study of dosing weight and outcomes for one pediatric dental sedation regimen. Pediatr Dent. 2018;40(5):346-351. [PubMed 30355430]
O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023-00777-y [PubMed 37256475]
O'Toole A, Lacroix J, Pratt M, Beecker J. Acute generalized exanthematous pustulosis associated with 2 common medications: hydroxyzine and benzocaine. J Am Acad Dermatol. 2014;71(4):e147-e149. doi:10.1016/j.jaad.2014.05.041 [PubMed 25219740]
Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. [PubMed 25711134]
Prenner BM. Neonatal withdrawal syndrome associated with hydroxyzine hydrochloride. Am J Dis Child. 1977;131(5):529-530. doi:10.1001/archpedi.1977.02120180043007 [PubMed 855838]
Refer to Canadian labeling.
Refer to manufacturer's labeling.
Roach CL, Husain N, Zabinsky J, Welch E, Garg R. Moderate sedation for echocardiography of preschoolers. Pediatr Cardiol. 2010;31(4):469-473. [PubMed 20047024]
Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426 [PubMed 14999113]
Rogal SS, Hansen L, Patel A, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022;76(3):819-853. doi:10.1002/hep.32378 [PubMed 35103995]
Roy-Byrne PP. Management of psychiatric disorders in patients with cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 2, 2021.
Sakaguchi T, Itoh H, Ding WG, et al. Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. J Pharmacol Sci. 2008;108(4):462-471. doi:10.1254/jphs.08178fp [PubMed 19057127]
Sawantdesai NS, Kale PP, Savai J. Evaluation of anxiolytic effects of aripiprazole and hydroxyzine as a combination in mice. J Basic Clin Pharm. 2016;7(4):97-104. doi:10.4103/0976-0105.189429 [PubMed 27999468]
Schlit AF, Delaunois A, Colomar A, et al. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. Pharmacol Res Perspect. 2017;5(3):e00309. doi:10.1002/prp2.309 [PubMed 28480041]
Serreau R, Komiha M, Blanc F, Guillot F, Jacqz-Aigrain E. Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. Reprod Toxicol. 2005;20(4):573-574. doi:10.1016/j.reprotox.2005.03.005 [PubMed 16199350]
Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med. 1994;330(23):1663-1670. doi:10.1056/NEJM199406093302307 [PubMed 7909915]
Simons FE, Simons KJ, Becker AB, Haydey RP. Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. J Pediatr. 1984b;104(1):123-127. doi:10.1016/s0022-3476(84)80608-3 [PubMed 6361228]
Simons FE, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. J Allergy Clin Immunol. 1984a;73(1 Pt 1):69-75. doi:10.1016/0091-6749(84)90486-x [PubMed 6141198]
Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol. 1989a;29(9):809-815. doi:10.1002/j.1552-4604.1989.tb03424.x [PubMed 2572611]
Simons KJ, Watson WT, Chen XY, Simons FE. Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. Clin Pharmacol Ther. 1989b;45(1):9-14. doi:10.1038/clpt.1989.2 [PubMed 2562944]
Snitker S, Doerfler RM, Soliman EZ, et al; for CRIC Study Investigators. Association of QT-prolonging medication use in CKD with electrocardiographic manifestations. Clin J Am Soc Nephrol. 2017;12(9):1409-1417. doi:10.2215/CJN.12991216 [PubMed 28793999]
Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol. 2014;70(11):1361-1366. [PubMed 25183382]
Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol. 2007;102(4):744-753. doi:10.1111/j.1572-0241.2006.01028.x [PubMed 17222324]
Staevska M, Gugutkova M, Lazarova C, et al. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol. 2014;171(1):148-154. doi:10.1111/bjd.12846 [PubMed 24472058]
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73(5):843-848. doi:10.1016/j.jaad.2015.07.017 [PubMed 26354880]
Thomas J, Saple DG, Jerajani HR, et al. Real-world, non-interventional, observational study of hydroxyzine hydrochloride in chronic pruritus: A prospective, non-comparative study. Dermatol Ther (Heidelb). 2019;9(2):299-308. doi:10.1007/s13555-019-0293-2 [PubMed 30949959]
Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905 [PubMed 32929996]
Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152 Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e57. [PubMed 23716032]
Tsai YS, Tu ME, Wu YH, Lin YC. Hydroxyzine-induced acute generalized exanthematous pustulosis. Br J Dermatol. 2007;157(6):1296-1297. doi:10.1111/j.1365-2133.2007.08225.x [PubMed 17927792]
Vigne J, Alexandre J, Fobe F, et al. QT prolongation induced by hydroxyzine: a pharmacovigilance case report. Eur J Clin Pharmacol. 2015;71(3):379-381. doi:10.1007/s00228-014-1804-9 [PubMed 25622983]
Vistaril (hydroxyzine) [prescribing information]. New York, NY: Pfizer; May 2023.
Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005 [PubMed 32439401]
Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Semin Dial. 2007;20(3):217-219. [PubMed 17555487]
Zeltzer LK, Krane EJ, Levy RL. Pediatric pain management. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020:chap. 76.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090 [PubMed 34536239]

Topic 8544 Version 806.0

خرید پکیج

Hydroxyzine: Drug information